Bristol-Myers shares drop; Regenera offers a lifeline to sinking Alcobra
→ The reverberations continue from Bristol-Myers Squibb’s missteps with Opdivo earlier this year. Shares dropped four percent this week as rumors of a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
